APS — Aptose Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- CA$7.78m
- CA$13.14m
Annual balance sheet for Aptose Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 122 | 79.1 | 47 | 9.25 | 6.15 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 125 | 81.7 | 49.5 | 11.9 | 9.53 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.19 | 0.788 | 1.51 | 1.09 | 0.597 |
| Total Assets | 126 | 82.5 | 51 | 13 | 10.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.81 | 8.17 | 12.3 | 15.3 | 4.46 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.35 | 8.29 | 13.3 | 15.9 | 14.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 119 | 74.2 | 37.7 | -2.9 | -4.54 |
| Total Liabilities & Shareholders' Equity | 126 | 82.5 | 51 | 13 | 10.1 |
| Total Common Shares Outstanding |